Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
出版年份 2013 全文链接
标题
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
作者
关键词
Combination therapy, Gemcitabine, Ovarian cancer, Oxaliplatinum, Platinum-resistant
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 32, Issue 1, Pages 49
出版商
Springer Nature
发表日期
2013-08-08
DOI
10.1186/1756-9966-32-49
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Weekly Administration of Bevacizumab, Gemcitabine, and Oxaliplatin in Patients With Recurrent and Refractory Ovarian Cancer
- (2013) Yuji Ikeda et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer
- (2012) Agustin A. Garcia et al. CANCER INVESTIGATION
- Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer
- (2012) Ilan Bruchim et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- The changing landscape of therapeutic strategies for recurrent ovarian cancer
- (2012) Klaus H Baumann et al. Future Oncology
- Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A Phase II study
- (2012) MA Salah-Eldin et al. INDIAN JOURNAL OF CANCER
- Clinical trials and future potential of targeted therapy for ovarian cancer
- (2012) Hiroaki Itamochi et al. International Journal of Clinical Oncology
- Therapeutic strategies in epithelial ovarian cancer
- (2012) Ayako Kim et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer
- (2011) Guillermo Crespo et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Platinum resistance in breast and ovarian cancer cell lines
- (2011) Niels Eckstein JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Overcoming platinum resistance in ovarian carcinoma
- (2010) Koji Matsuo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
- (2010) Mansoor Raza Mirza et al. GYNECOLOGIC ONCOLOGY
- Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
- (2009) I Ray-Coquard et al. BRITISH JOURNAL OF CANCER
- Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study
- (2009) F. Joly et al. GYNECOLOGIC ONCOLOGY
- Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
- (2008) Daniela D. Rosa et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
- (2008) Howard Hochster et al. GYNECOLOGIC ONCOLOGY
- A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
- (2008) Faruk Tas et al. International Journal of Clinical Oncology
- Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
- (2008) Jalid Sehouli et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started